CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2020		Dec. 31, 2019
Real estate properties:
Land	$ 786,242		$ 793,123
Buildings and improvements	6,648,430		6,668,463
Total real estate properties, gross	7,434,672		7,461,586
Accumulated depreciation	(1,612,328)		(1,570,801)
Total real estate properties, net	5,822,344		5,890,785
Assets of properties held for sale	244,881		209,570
Cash and cash equivalents	69,545		37,357
Restricted cash	15,691	[1]	14,867
Acquired real estate leases and other intangible assets, net	323,134		337,875
Other assets, net	228,128		163,372
Total assets	6,703,723		6,653,826
Liabilities and Equity
Unsecured revolving credit facility	585,000		537,500
Unsecured term loans, net	449,035		448,741
Senior unsecured notes, net	1,821,560		1,820,681
Secured debt and capital leases, net	693,961		694,739
Liabilities of properties held for sale	8,218		6,758
Accrued interest	29,236		24,060
Assumed real estate lease obligations, net	74,430		76,705
Other liabilities	255,114		167,592
Total liabilities	3,916,554		3,776,776
Commitments and contingencies
Equity attributable to common shareholders:
Common shares of beneficial interest, $.01 par value: 300,000,000 shares authorized, 237,893,725 and 237,897,163 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	2,379		2,379
Additional paid in capital	4,612,739		4,612,511
Cumulative net income	2,062,297		2,052,562
Cumulative distributions	(4,026,418)		(3,930,933)
Total equity attributable to common shareholders	2,650,997		2,736,519
Noncontrolling interest:
Total equity attributable to noncontrolling interest	136,172		140,531
Total equity	2,787,169		2,877,050
Total liabilities and equity	$ 6,703,723		$ 6,653,826

[1] Restricted cash consists of amounts escrowed for real estate taxes, insurance and capital expenditures at certain of our mortgaged properties and cash held for the operations of one of our life science properties that is owned in a joint venture arrangement in which we own a 55% equity interest.